Suramin
- 31 July 1994
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 20 (3), 259-273
- https://doi.org/10.1016/0305-7372(94)90003-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor αInternational Journal of Immunopharmacology, 1992
- Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells.JCI Insight, 1992
- Suramin Blockade of Insulinlike Growth Factor I-Stimulated Proliferation of Human Osteosarcoma CellsJNCI Journal of the National Cancer Institute, 1990
- Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated diseaseEuropean Journal of Cancer and Clinical Oncology, 1990
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Suramin therapy in AIDS and related disorders. Report of the US Suramin Working GroupJAMA, 1987
- Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-IIIScience, 1984
- The Population Approach to Pharmacokinetic Data Analysis: Rationale and Standard Data Analysis MethodsDrug Metabolism Reviews, 1984
- Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor virusesCancer Letters, 1979